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Purpose: To construct tissue engineered corneal epithelium from a clinical-grade human embryonic stem cells
(hESCs) and investigate the dynamic gene profile and phenotypic transition in the process of differentiation.
Methods: A stepwise protocol was applied to induce differentiation of clinical-grade hESCs Q-CTS-hESC-1 and
construct tissue engineered corneal epithelium. Single cell RNA sequencing (scRNA-seq) analysis was performed
to monitor gene expression and phenotypic changes at different differentiation stages. Immunostaining, real-
time quantitative PCR and Western blot analysis were conducted to detect gene and protein expressions. After
subcutaneous transplantation into nude mice to test the biosafety, the epithelial construct was transplanted in a
rabbit corneal limbal stem cell deficiency (LSCD) model and followed up for eight weeks.
Results: The hESCs were successfully induced into epithelial cells. scRNA-seq analysis revealed upregulation of
ocular surface epithelial cell lineage related genes such as TP63, Pax6, KRT14, and activation of Wnt, Notch,
Hippo, and Hedgehog signaling pathways during the differentiation process. Tissue engineered epithelial cell
sheet derived from hESCs showed stratified structure and normal corneal epithelial phenotype with presence of
clonogenic progenitor cells. Eight weeks after grafting the cell sheet onto the ocular surface of LSCD rabbit
model, a full-thickness continuous corneal epithelium developed to fully cover the damaged areas with normal
limbal and corneal epithelial phenotype.
Conclusion: The tissue engineered corneal epithelium generated from a clinical-grade hESCs may be feasible in
the treatment of limbal stem cell deficiency.
1. Introduction
The transparent cornea is crucial for normal vision. One of the re-
quirements for sustaining corneal transparency is preserving the
structural integrity of the stratified epithelium on the surface layer of
the cornea [1,2]. To meet this requirement, the corneal epithelium
needs to maintain self-renewal during homeostasis, a property which is
governed by corneal epithelial stem cells. It is well accepted that human
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corneal epithelial stem cells are located at the basal layer of corneal
limbus, i.e., the palisades of Vogt at the junction between the cornea
and the conjunctiva [3–7]. Various clinical conditions in the cornea,
such as acute trauma, chemical or thermal injury, Stevens-Johnson
syndrome and genetic disorders like aniridia, can cause partial or total
limbal stem cell deficiency (LSCD), thereby compromising the home-
ostasis of the corneal epithelium to cause corneal conjunctivalization,
opacification, and neovascularization, all of which can eventually cause
vision loss or even blindness [8–16]. LSCD is one of the leading causes
of irreversible vision loss in the world, especially in the developing
countries.
Over the past two decades, different strategies have been developed
to treat LSCD. Autologous limbal tissue transplantation has been ap-
plied to treat unilateral LSCD [17,18]. Conjunctival transplantation,
limbal allograft transplantation, and tissue engineered corneal epithe-
lial transplantation have been used in bilateral LSCD [19–23]. To
construct tissue engineered corneal epithelium, different cell sources
including hair follicle stem cells, oral mucosal epithelial cells, dental
pulp stem cells, nasal mucosal epithelial cells, induced pluripotent stem
cells (hiPSCs) or human embryonic stem cells (hESCs) have been em-
ployed, and some have been successfully applied in the clinic [24–34].
General interest in using hESC-derived cells for cell therapy has
been rising due to their relatively unlimited cell availability and the
development of robust lineage differentiation protocols. The first hESC-
derived retinal pigmented epithelial cells transplantation that proved to
be safe was performed in 2012 in patients with Stargardt's macular
dystrophy [35]. Another hESC-derived cardiac progenitors transplan-
tation for severe heart failure provided symptomatic improvement
without any complications [36]. For severe ocular surface diseases,
mouse ESC-derived corneal epithelial progenitors were first used for
epithelial reconstruction of damaged mouse corneal epithelium in 2004
[37]. While different protocols have been reported to induce the dif-
ferentiation of hESCs into corneal epithelium-like cells [24,38,39], the
cellular phenotypic changes underwent during the sequential differ-
entiation procedures were not well defined, and their final cell fate after
transplantation into animal models had remained elusive.
In this study, we applied a stepwise differentiation protocol to
generate corneal epithelial cell sheets from the first Chinese clinical-
grade hESC line Q-CTS-hESC-1 [40]. We profiled 29,812 single-cell
transcriptomes at multiple time points throughout the entire differ-
entiation procedure using single-cell RNA-sequencing (scRNA-seq) and
reconstructed their cell fate trajectories. Moreover, various functional
assays were performed to characterize the phenotype of the cells at
different stages. Our protocol successfully generated corneal epithelial
progenitor cells and tissue-engineered epithelium cell sheets using
hESCs, to restore ocular function in a LSCD rabbit model[53].
2. Results
2.1. Stepwise differentiation of hESC line
Q-CTS-hESC-1 is the first Chinese clinical-grade human embryonic
cell line that meets the requirements of the China Food and Drug
Administration [40]. This cell line is maintained in a serum-free and
feeder cell-free culture system over the long-term. To generate corneal
epithelial progenitor cells, the entire differentiation process is demar-
cated into four stages, stage I as the hESCs stage, stage II as the neural
sphere culture stage (NP), stage III as the epithelial progenitor cells
stage, stage IV as the corneal epithelial cell sheet (ES-CE) stage, re-
spectively (Fig. 1A).
In total, 29,812 single cells from 4 time points throughout the dif-
ferentiation process (13052, 8869, 1602, 6289 cells from stage I, II, III,
IV, respectively) were used for single-cell sequencing analysis. The gene
expression profiles were measured with the Chromium System
(10 × Genomics), a high-throughput and parallel droplet-based scRNA-
seq platform [41]. We projected all single cells onto a t-distributed
stochastic neighbor embedding (t-SNE) plot and 4 original cell clusters
were identified from the 4 different stages: stage I to stage IV cells
(Fig. 1B). Our analysis revealed there were some cells that permeated
from stage II to stage I, and from stage IV to stage III (Fig. 1B). How-
ever, compared with the 4 transcriptionally distinct clusters of cells
identified from the 4 differentiation stages (Fig. 1C), cluster I appeared
to contain mostly stage I cells and some stage II cells, suggesting that
some cells had already begun epithelial differentiation during the stage
I expansion of hESCs or that some stage II cells had remained un-
differentiated as hESCs. Similarly, cluster III appeared to contain mostly
stage III cells and some stage IV cells, suggesting that some cells from
stage III had already begun to acquire the phenotype of stage IV cells or
that some stage IV cells had in fact remained undifferentiated as epi-
thelial progenitor cells. Interestingly, there is no overlap between stage
I cells and stage III cells or stage IV cells, nor between stage II cells and
stage III cells or stage IV cells, which suggests there is a dramatic dif-
ference in phenotypes between these stages. We further analyzed the
gene expression profiles from different stages and found that cells from
the stage I hESCs (SI) were quite homogenous (Fig. 1D), while the cells
from stage II (SII, Fig. 1E), stage III (SIII, Fig. 1F), and stage IV (SIV,
Fig. 1G) were more heterogeneous and could be divided into more than
three subgroups.
2.2. Characterization of cells differentiated from hESCs
We further characterized the cells at different differentiation stages.
Immunofluorescent staining showed that the embryonic stem cell
marker OCT4 was highly expressed in stage I and dramatically de-
creased by stage III and stage IV. On the other hand, the epithelial
progenitor cell marker TP63 was almost negative in stage I, while it was
highly expressed in some nuclei of stage II, III and IV cells. Pax6, the
lineage differentiation marker of ocular surface epithelium, was highly
expressed from stage II to IV. We also found that keratin 14 (KRT14)
and pan-cytokeratin (Pan-CK) were gradually increased from stage II to
IV, indicating epithelial lineage differentiation from hESCs (Fig. 2A).
Quantitative real-time PCR confirmed the expression pattern of OCT4
(Fig. 2B), TP63 (Fig. 2C), Pax6 (Fig. 2D), and KRT14 (Fig. 2E) in dif-
ferent stages of differentiation. Western blot analysis further demon-
strated the expression of TP63, Pax6, and KRT14 proteins at different
stages, and had similar gene expression patterns (Fig. 2F).
To identify the cell population at different stages, we refined the
clustering analyses at each differentiation stage based on lineage-spe-
cific marker expression in single cell RNA-seq. We found that the hESC
markers OCT4 and NANOG were highly expressed in stage I and had
almost disappeared by stage IV. OCT4 was positive in 34.95% of stage II
cells and accumulated as a certain group of cells with strong expression.
However, it was positive in 47.82% of stage III cells and scattered
throughout the whole population with weak expression (Fig. 3A). This
is in accordance with qRT-PCR results (Fig. 2B). We also found that
stage I cells were almost completely negative for TP63, while it peaked
at 10.49% in stage III cells, and remained at 6.36% in stage IV cells.
Pax6 was positive in 6.98% of stage II cells and were maintained at
3.31% in stage IV cells. TP63 and Pax6 double positive cells were first
detected at 0.44% in stage III cells, and were maintained at 0.25% in
stage IV cells, indicating the successful derivation of corneal epithelial
progenitor cells (Fig. 3A).
We then expanded our single-cell resolution gene expression pro-
filing to other lineage-specific markers, to identify different categories
of cells during the differentiation process. Based on POU5F1, NANOG
and DPPA2 expression, the hESC population gradually decreased from
stage II to stage IV. Based on NGFR, SOX10, FOXD3 expression, some of
these cells exhibited a neural crest cell phenotype at stage II, which may
have resulted from neural sphere culture conditions. Based on KRT8,
KRT18, KRT19 expression, the epithelial ectoderm cells gradually in-
creased with time from stage II to stage IV. Based on ABCG2, LGR5,
TP63, KRT14, KRT15, Pax6 expression, the corneal epithelial
J. He, et al. The Ocular Surface 18 (2020) 672–680
673
progenitor cell population reached a peak at stage III, and underwent a
small decrease at stage IV. Interestingly, based on KRT3, KRT12, KRT1,
SPRR1B expression, terminal differentiated corneal or skin epithelial
cell populations both remained at low levels at stage IV. The me-
senchymal cell population, based on PRRX1, TWIST2, SNAI1 expres-
sion, also remained at very low levels in our culture system (Fig. 3B). A
kinetic analysis of the proportions of different cell-types at different
stages further demonstrated that critical differentiation of human em-
bryonic stem cells occurred at stage II, while corneal lineage commit-
ment happened at stage III (Fig. 3C).
We then applied the Human Primary Cell Atlas (HPCA) reference
dataset as a reference library to perform the single-cell recognition
(SingleR) annotation on the cells from different stages. The results
further confirmed that in stage I, most of the cells were pluripotent
hESCs. In stage II, the cells were mostly neuroepithelial cells, combined
with a few neurons, pluripotent stem cells, and some mesenchymal
stem cells. In stage III, most of the cells were epithelial cells combined
with some pluripotent stem cells and mesenchymal stem cells. In stage
IV, most of the cells were epithelial cells, with a few pluripotent stem
cells (Fig. 3D). This annotation confirmed the high efficiency of our
differentiation protocol in generating epithelial cells from hESCs.
We then determined which typical gene expression patterns were
present in our tissue engineered epithelial cell sheet at stage IV. The
results showed that almost all cells expressed the epithelial markers
KRT19 (98.97%) and KRT7 (99.65%), whereas 40.61% of cells ex-
pressed ABCG2, one of the epithelial progenitor cell markers. Two
stratified epithelial progenitor cell markers KRT14 (4.96%) and KRT15
(4.91%) were also present, albeit at low frequency, in stage IV cells.
However, the skin epithelial terminal differentiation marker KRT1 and
the corneal epithelial terminal differentiation marker KRT12 were both
negative. The conjunctival epithelial marker KRT13 (0.03%) and an-
other terminally differentiated corneal epithelial marker KRT3 (0.03%)
were also present at very low frequencies (Fig. 3E). Thus our data
analysis indicates that the majority of the cells at stage IV were epi-
thelial progenitor cells.
2.3. Activation of major developmental signaling pathways during
differentiation procedure
To determine the activation of stem cell-related signaling pathways
during the differentiation procedure, we re-analyzed the single-cell
RNA sequencing data. We found that the Wnt signaling pathway mar-
kers were activated from stage II onwards (Fig. 4A). Immunostaining
showed significant nuclear translocation of β-catenin by stage III
(Fig. 4B). Western blot results further confirmed upregulation of β-ca-
tenin and phospho-β-catenin from stage II onwards (Fig. 4C). Quanti-
tative RT-PCR of Wnt signaling pathway related genes further con-
firmed upregulation of Axin2 by stage III (Fig 4D) and c-Myc at stage II
(Fig. 4E), while cyclin D1 underwent downregulation at stages III and
IV (Fig. 4F). The Notch pathway was upregulated at stage II and III,
along with gradual activation of the TGF-β pathway from stage II to
stage IV (Fig. 4G). The Hippo and Hedgehog signaling pathways were
also gradually activated at stages II and III, but downregulated at stage
IV (Fig. 4G).
2.4. Evaluation of clonogenicity and tumorigenicity of induced corneal
epithelial stem cells (ES-CE)
At the end of stage III, hESC-derived cells were harvested from
plastic dishes and seeded on an epithelial denuded amniotic membrane
(dAM) and cultured for another 7 days (Fig. 5A). The phase contrast
images showed a compact and intact ES-CE cell sheet (Fig. 5B). H&E
staining of the cell sheet cross-sections demonstrated 2 to 3 layers of a
tissue engineered epithelium (Fig. 5C). Immunofluorescent staining
showed positive expression of Pax6, TP63, E-cadherin, Pan-CK, KRT14
and KRT3/KRT12 proteins in the epithelial cell sheet (Fig. 5D-I).
To functionally determine whether the engineered epithelial cell
sheet contained epithelial progenitor cells, we harvested cells from the
end of stage IV and seeded them onto 3T3 feeder layers to elucidate the
clonogenicity of the induced ES-CE. Notably, clones appeared on day 4,
increased in size with time, and formed typical round epithelial co-
lonies at day 7 (Fig. 5J). Immunofluorescent staining was performed on
colonies cultured for 7 days and the results showed that the majority of
the cells inside the colonies expressed Pax6, which indicates the ocular
Fig. 1. The differentiation process for human embryonic stem cells to corneal progenitor cells. Schematic illustration of optimized protocol used for the
construction of tissue engineered corneal epithelial stem cells from hESCs (A). t-SNE projection of all 29,812 individual cells during the whole differentiation process,
colored by indicated time points (B). t-SNE projection of all 29,812 individual cells during the whole differentiation process, colored by clusters (C). t-SNE projection
for 4 stages cells, colored by clusters (D–G).
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surface lineage of the cells (Fig. 5K). TP63 was strongly expressed in the
nuclei of peripheral cells inside the colonies (Fig 5L). Pan-CK (Fig 5M)
and KRT14 (Fig 5N) were expressed in the majority of the cells, whereas
the terminally differentiated corneal epithelial cell markers KRT3/
KRT12 were absent (Fig 5O).
To determine the biosafety of ES-CE cells, the engineered cell sheet
was subcutaneously transplanted into nude mice. Positive and negative
controls were generated by transplanting hESCs and a dAM sheet, re-
spectively. Eight weeks post-surgery, the negative control group (Fig
5P) and ES-CE group (Fig 5Q) showed that the transplantation area had
a normal appearance, while teratoma formation was evident in the
hESCs transplantation group (Fig 5R). H&E staining further confirmed
the typical three germ layers structure of the teratoma (Fig. S1).
Therefore, our results showed that the ES-CE generated from our pro-
cedure contained epithelial progenitor cells of ocular surface lineage
and they are safe for in vivo transplantation.
2.5. Transplantation of tissue-engineered epithelial cell sheet in rabbit LSCD
model
To determine if the hESC derived epithelial cell sheet is capable of
reconstructing a damaged ocular surface, we generated a limbal stem
cell deficient (LSCD) rabbit model, through surgical removal of the
entire corneal epithelium and limbal tissue. After that, ES-CE with dAM
carrier was mounted onto the ocular surface with fibrin glue, while a
control AM group received dAM alone. Slit lamp examination and
fluorescein staining of the ocular surface were performed every two
weeks. Eight weeks after surgery, the cornea of the ES-CE transplan-
tation group became transparent in the center, and the grafted epi-
thelium appeared smooth, with rare fluorescein positive staining and
peripheral neovascularization. In contrast, rough corneal epithelial
surface, corneal opacity, random neovascularization, and intense
fluorescein staining of the central cornea was observed in the dAM
Fig. 2. Characterization of the induced cells from hESCs. Immunofluorescence staining results show significant expression of embryonic stem cell marker in stage
I cells. Ocular surface lineage epithelial markers Pax6, Pan-CK and KRT14 were expressed in stage II to stage IV, epithelial progenitor cell marker TP63 was also
expressed in stage II to stage IV (A), scale bar represents 20 μm qRT-PCR results for OCT4, TP63, Pax6, KRT14 during the 4 stages of differentiation (B–E). Western
blot results for TP63, Pax6 and KRT14 expressed in 4 stages (F).
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Fig. 3. High-resolution dissection of differentiation process from hESCs to epithelium progenitor cells using scRNA-Seq. t-SNE projection of cells and typical
gene expressions (OCT4, NANOG, TP63, Pax6 and TP63+ Pax6) in the 4 different stages (A). Expression of genes in 3 different categories at the indicated time points
(B). Percentages of cell types at different time points (C). SingleR annotation of cell identity indicated on t-SNE plot (D). t-SNE projection of cells and typical gene
expression (ABCG2, KRT14, KRT15, KRT19, KRT7, KRT1, KRT13, KRT3 and KRT12) in stage IV (E).
Fig. 4. The Wnt/β-catenin pathway and other signaling pathways in hESCs differentiation. Heat map depicting the Wnt signal pathway genes expression in 4
stages (A). The expression of β-catenin in 4 stages by immunofluorescence staining, in stage III, the β-catenin were detected in the nucleus (B), scale bar represents
20 μm. The expression of β-catenin and phospho-β-catenin (p-β-catenin) in 4 stages by Western blot (C). qRT-PCR results for Axin2 (D), c-myc (E), cyclin D1 (F) in the
4 stages of differentiation. Heatmap depicting the expression of Notch, TGF-β, Hippo, and Hedgehog signal pathway genes in 4 stages of hESCs differentiation (G).
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transplantation group (Fig. 6). Thus, our results indicate that the ES-CE
sheets are capable of reconstructing the ocular surface after trans-
plantation onto LSCD rabbit models in vivo.
2.6. Survival and in vivo differentiation of hESC derived cells on the ocular
surface of LSCD rabbit model
To further confirm the survival of engineered epithelial cell sheet
and restoration of the damaged limbal area on the compromised ocular
surface, the rabbits were sacrificed 8 weeks after the surgery. H&E
staining of the corneal cryosections showed that normal histological
integrity of both the limbal and central corneal epithelium was restored
in the ES-CE transplanted animals, while dAM transplanted cornea
showed dramatic increases in cell infiltration into the stroma with just
2–3 irregular stratified layers of epithelial cells. Human nuclear antigen
expression was identified in both the limbal and the central cornea of
the ES-CE group, which confirmed survival of the hESC derived cells at
8 weeks post transplantation. There was human-specific Pax6 staining
Fig. 5. Tissue engineering with induced
corneal epithelial stem cells. The AM
construct (A). Morphology of engineered
cell sheet (B). H&E staining (C).
Immunofluorescence staining of corneal
epithelial markers Pax6, TP63, E-cadherin,
Pan-CK, KRT14 (D–H) and the KRT3/KRT12
duplex (I). Induced epithelial cells from
stage IV were seeded on 3T3 feeder layers
and generated epithelial clones (J). The
clones at day 7 expressed Pax6, TP63, Pan-
CK, KRT14 (K–N), while was negative of
KRT3/KRT12 expression (O). Negative
control with dAM was transplanted sub-
cutaneously in nude mice for 8 weeks, and
there was no tumor formation (P).
Epithelial cell sheet from stage IV showed
similar results (Q), while transplantation of
hESCs on AM resulted in teratoma forma-
tion (R). Scale bars represent 20 μm.
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in the reconstructed epithelium in the ES-CE transplantation group,
while it was negative in the AM control and normal control group. Pan-
CK was expressed in all layers of the central and limbal epithelium cells
in all three groups. The positive staining also revealed an epithelial
structural pattern, whereby the ES-CE group showed a well-stratified
corneal and limbal epithelium, while the epithelium was much thinner
and non-stratified in the AM control group. KRT14 was mainly ex-
pressed in the basal layer of the limbal and central corneal epithelium
in ES-CE group, while it was weakly expressed in the AM control group.
KRT3/KRT12 was expressed in the suprabasal layer of the central
corneal epithelium and it was negative in the limbal epithelium of the
ES-CE group, indicating normal corneal epithelial lineage terminal
differentiation of the stage IV cells after orthotopic transplantation.
However, discontinuous KRT3/KRT12 staining was observed in the
central cornea, and KRT3/KRT12 were completely negative in the
limbal epithelium of the AM group (Fig. 7). Taken together, these re-
sults demonstrated that hESC-derived cells survived on the rabbit
ocular surface 8 weeks after orthotopic transplantation, and they could
efficiently differentiate into a corneal epithelial phenotype.
3. Discussion
In this study, we generated a corneal epithelial cell sheet derived
from the first Chinese clinical grade embryonic stem cell line Q-CTS-
hESC-1, and successfully transplanted this ES-CE cell sheet with a de-
nuded amniotic membrane scaffold onto a LSCD rabbit model to re-
construct the ocular surface. Eight weeks after ES-CE cell sheet trans-
plantation, the construct became transparent in the corneal area with
well-stratified corneal terminal differentiation and peripheral neo-
vascularization in the limbus. This outcome confirmed the desirability
of performing reconstruction surgery with the hESCs-derived tissue-
engineered corneal epithelium construct.
Different protocols have been applied to induce differentiation of
hESCs into corneal epithelial cells [24,38,39,42]. The differentiation
time varies from 2 to 8 weeks. In addition, the differentiation media
were also highly variable, with the presence or the absence of feeder
cells. In our 4-step differentiation protocol, it took about 3 weeks to
generate a sufficiently large epithelial cell sheet suitable for trans-
plantation without application of feeder cells. Our protocol is ad-
vantageous because of its relative simplicity and speed in generating an
intact and sufficiently large epithelial sheet suitable for epithelial re-
construction.
The corneal epithelium is a well-stratified, non-keratinized and
transparent physical barrier to protect the eye against pathogenic
Fig. 6. Reconstruction of rabbit ocular surface with hESCs derived epi-
thelium. Epithelial cell sheet from stage IV (ES-CE) was transplanted onto
ocular surface of LSCD rabbit model. Slit lamp examination and fluorescein
staining on the ocular surface was performed every two weeks. Eight weeks
after surgery, the cornea of ES-CE transplantation group was transparent and
the grafted epithelium appeared smooth, with rare fluorescein positive staining
and peripheral neovascularization. In contrast, rough corneal epithelial surface,
corneal opacity, neovascularization, intense fluorescein staining of central
cornea was observed in the dAM transplantation group.
Fig. 7. Characterization of limbal epithelium and central corneal epithelium at 8 weeks post-surgery. H&E staining showed limbal structure and central
corneal epithelium was well re-constructed after ES-CE cell sheet transplantation. Human nuclei staining was positive in ES-CE cell sheet transplanted cornea. Pax6
(human specific Pax6 antibody), Pan-CK, KRT14, and KRT3/KRT12 was expressed in both limbal and central cornea of ES-CE cell sheet transplanted cornea. Scale bar
represents 20 μm.
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infiltration, and contributes to the maintenance of corneal homeostasis.
Cytokeratin KRT12 is a unique biomarker for the terminally differ-
entiated corneal epithelium, which is not expressed in other stratified
epithelial cells such as conjunctival, oral mucosal, and skin epithelium
[5]. The transcription factor Pax6 regulates keratin KRT12 gene and
protein expression [43,44]. Pax6 determines the ocular surface lineage
commitment during embryonic development [45], and also in different
diseases [46,47]. Therefore, induction of Pax6 gene expression is cri-
tical for promoting hESC differentiation and in turn engineering an
intact corneal epithelial layer. In our differentiation protocol, a sphe-
rical culture was established in stage II to dramatically increase Pax6
gene expression. Although Pax6 expression declined during stages III
and IV, it was still expressed throughout stage IV. On the other hand,
two epithelial progenitor markers, TP63 and KRT14, were gradually
upregulated from stage II to stage IV. Therefore, after stage II differ-
entiation, the cells were driven into the ocular surface epithelial
lineage. This commitment was confirmed based on the results of im-
munostaining, real time PCR and Western blot analysis. Interestingly,
we found cells in stage IV present certain phenotype of conjunctival
epithelial cells, which showed strong expression of KRT7 and KRT19. At
the meantime, another conjunctival epithelial cell marker KRT13 ex-
pression was very low in stage IV cells. Since KRT19 is also highly
expressed in corneal limbal epithelial cells, together with high level
expression of ABCG2, KRT14 and low level of KRT3 and KRT12, we
highly suspect that cells in stage IV maintained limbal stem/progenitor
phenotype. More importantly, almost all of the epithelial cells trans-
planted onto the rabbit ocular surface maintained a high level of Pax6
expression and KRT3/KRT12 expression in the central cornea for eight
weeks after orthotopic transplantation, supports the notion that hESC-
derived epithelial cells can commit final differentiation to corneal
epithelial phenotype in vivo. We suspect that the ocular surface mi-
croenvironment may facilitate corneal lineage differentiation of the
hESC-derived epithelial cells.
This study used the scRNA-seq technique for the first time to de-
scribe the stage dependent changes in phenotype and gene expression
profiles that underlie the transitions from hESCs to corneal epithelial
cells. From the gene expression profile trajectories, we could appreciate
that the suspension sphere culture at stage II induced rapid differ-
entiation of hESCs to generate Pax6 positive cells, while the attachment
culture at stage III augmented increases in TP63 positive cells. Our t-
SNE projection of the cells demonstrated that 0.44% of the cells were
co-labeled with Pax6 and TP63 at the end of stage III. Although this
percentage is low, we suspect these cells may represent resident corneal
epithelial stem cells within our tissue engineered epithelium construct.
This is supported by the clonogenicity assay at the end of stage IV,
which produced colonies that highly expressed Pax6, TP63 and KRT14.
The Wnt/β-catenin signaling pathway is a major regulator of cor-
neal epithelial lineage differentiation [48] and stratification during
morphogenesis [49]. Notch signaling pathway is also involved in
maintaining the homeostatic function of corneal epithelial stem cells
and cell fate determination [50,51]. In our study, we analyzed the
major signaling pathways involved in the differentiation process from
hESC to corneal epithelium based on scRNA-seq data. The results re-
vealed that Wnt, Notch, Hippo and Hedgehog signaling pathways were
all activated at stage II and stage III. The TGF-β pathway was gradually
activated during differentiation from stage II to stage IV. Additional
studies are warranted to clarify if crosstalk between different signaling
pathways affects their regulation of corneal epithelial differentiation.
For the first time, we orthotopically transplanted a clinical grade
hESC-derived corneal epithelial cell sheet into a rabbit LSCD model. At
the follow up after 8 weeks, the clinical outcome was promising. The
corneal epithelium became transparent in the center and remained in-
tact on the recipient cornea, without any signs of immune rejection. H&
E staining revealed that the limbal and central corneal epithelial
structure of the recipient cornea was similar to that of the normal
control. Human nuclear antigen staining was apparent, proving the
survival of transplanted cells. Intriguingly, the transplanted cells
maintained a stable ocular surface epithelial phenotype based on pro-
nounced Pax6 expression. Furthermore, KRT14 expression was evident
in the basal epithelial layer, while the KRT3/KRT12 duplex was ex-
pressed in the suprabasal layers. These results showing the re-
appearance of a normal histological structure and a physiological
phenotype of both limbal and corneal epithelium is remarkable.
Accordingly, we foresee that this result will prompt interest in initiating
clinical trials to test if this procedure can be implemented to use hESC-
derived corneal epithelial cells in the treatment of severe ocular surface
diseases in human.
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